Paul A Beavis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3408608/publications.pdf

Version: 2024-02-01

65 papers	8,288 citations	94433 37 h-index	98798 67 g-index
72 all docs	72 docs citations	72 times ranked	12943 citing authors

#	Article	IF	Citations
1	PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. Cancer Discovery, 2022, 12, 752-773.	9.4	52
2	Differential location of NKT and MAIT cells within lymphoid tissue. Scientific Reports, 2022, 12, 4034.	3.3	2
3	CD4⁺ chimeric antigen receptor T cells in for the long journey. Immunology and Cell Biology, 2022, 100, 304-307.	2.3	3
4	Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer. Journal of Clinical Oncology, 2022, , JCO2200284.	1.6	1
5	TGFÎ² and CIS Inhibition Overcomes NK-cell Suppression to Restore Antitumor Immunity. Cancer Immunology Research, 2022, 10, 1047-1054.	3.4	11
6	Cellular networks controlling T cell persistence in adoptive cell therapy. Nature Reviews Immunology, 2021, 21, 769-784.	22.7	83
7	CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nature Communications, 2021, 12, 3236.	12.8	99
8	Myeloma natural killer cells are exhausted and have impaired regulation of activation. Haematologica, 2021, 106, 2522-2526.	3.5	8
9	CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory. Cancer Discovery, 2021, 11, 2582-2601.	9.4	62
10	The role of exhaustion in CAR T cell therapy. Cancer Cell, 2021, 39, 885-888.	16.8	35
11	MAIT cells regulate NK cell-mediated tumor immunity. Nature Communications, 2021, 12, 4746.	12.8	45
12	Adoptive transfer of tumor-specific Th9 cells eradicates heterogeneous antigen-expressing tumor cells. Cancer Cell, 2021, 39, 1564-1566.	16.8	5
13	Augmenting Adoptive T-cell Immunotherapy by Targeting the PD-1/PD-L1 Axis. Cancer Research, 2021, 81, 5803-5805.	0.9	4
14	<scp>PTPN</scp> 2 phosphatase deletion in T cells promotes antiâ€tumour immunity and <scp>CAR</scp> Tâ€cell efficacy in solid tumours. EMBO Journal, 2020, 39, e103637.	7.8	79
15	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. Molecular Therapy, 2020, 28, 2379-2393.	8.2	49
16	Pharmacological and genetic strategies for targeting adenosine to enhance adoptive T cell therapy of cancer. Current Opinion in Pharmacology, 2020, 53, 91-97.	3.5	5
17	Targeting the epigenetic regulation of antitumour immunity. Nature Reviews Drug Discovery, 2020, 19, 776-800.	46.4	264
18	Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion. Cancer Research, 2020, 80, 4129-4144.	0.9	179

#	Article	IF	Citations
19	Editorial overview: Cancer 2020 current mechanistic insights into the hypoxia-adenosine-A2A adenosinergic immunosuppressive axis in cancer immunotherapies. Current Opinion in Pharmacology, 2020, 53, iii-v.	3.5	1
20	Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nature Immunology, 2020, 21, 914-926.	14.5	114
21	p38 Kinase: A Key Target for Driving Potent T Cells for Adoptive Immunotherapy. Cancer Cell, 2020, 37, 756-758.	16.8	3
22	Promising Immuno-Oncology Options for the Future: Cellular Therapies and Personalized Cancer Vaccines. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e253-e258.	3.8	8
23	Efficient CRISPR/Cas9 Gene Editing in Uncultured Naive Mouse T Cells for In Vivo Studies. Journal of Immunology, 2020, 204, 2308-2315.	0.8	40
24	Sex-specific adipose tissue imprinting of regulatory T cells. Nature, 2020, 579, 581-585.	27.8	141
25	Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nature Reviews Clinical Oncology, 2020, 17, 341-348.	27.6	159
26	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clinical Cancer Research, 2020, 26, 487-504.	7.0	355
27	A New Safety Approach Allowing Reversible Control of CAR T Cell Responses. Molecular Therapy, 2020, 28, 1563-1566.	8.2	0
28	CAR T cells take centre stage. Clinical and Translational Immunology, 2019, 8, e01068.	3.8	1
29	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell, 2019, 36, 385-401.e8.	16.8	359
30	Supercharging adoptive T cell therapy to overcome solid tumorâ€“induced immunosuppression. Science Translational Medicine, 2019, 11, .	12.4	100
31	Switching on the green light for chimeric antigen receptor Tâ€cell therapy. Clinical and Translational Immunology, 2019, 8, e1046.	3.8	11
32	Tissueâ€specific tumor microenvironments influence responses to immunotherapies. Clinical and Translational Immunology, 2019, 8, e1094.	3.8	20
33	Antagonism of IAPs Enhances CAR T-cell Efficacy. Cancer Immunology Research, 2019, 7, 183-192.	3.4	68
34	Tumorâ€derived exosomes modulate T cell function through transfer of RNA. FEBS Journal, 2018, 285, 1030-1032.	4.7	6
35	Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2068-E2076.	7.1	224
36	T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma. OncoImmunology, 2018, 7, e1365997.	4.6	2

#	Article	IF	Citations
37	Targeting Adenosine Receptor Signaling in Cancer Immunotherapy. International Journal of Molecular Sciences, 2018, 19, 3837.	4.1	139
38	Tumor immune evasion arises through loss of TNF sensitivity. Science Immunology, 2018, 3, .	11.9	244
39	Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3â^' Cellâ€"Mediated Modulation of CD103+ Dendritic Cells. Cancer Immunology Research, 2018, 6, 1069-1081.	3.4	67
40	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nature Medicine, 2018, 24, 986-993.	30.7	689
41	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. Cancer Research, 2017, 77, 1296-1309.	0.9	61
42	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Reports, 2017, 18, 2162-2174.	6.4	244
43	A novel combination strategy for effectively targeting cancer stemâ€like cells. Immunology and Cell Biology, 2017, 95, 573-574.	2.3	3
44	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. Clinical Cancer Research, 2017, 23, 2478-2490.	7.0	95
45	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nature Communications, 2017, 8, 606.	12.8	89
46	A Novel Target Antigen for the Treatment of Acute Myeloid Leukemia by CAR T Cells. Molecular Therapy, 2017, 25, 1997-1998.	8.2	2
47	CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature, 2017, 549, 101-105.	27.8	624
48	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. Journal of Clinical Investigation, 2017, 127, 929-941.	8.2	251
49	Immunosuppressive activities of adenosine in cancer. Current Opinion in Pharmacology, 2016, 29, 7-16.	3.5	216
50	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Seminars in Immunology, 2016, 28, 64-72.	5.6	52
51	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clinical Cancer Research, 2016, 22, 1499-1509.	7.0	428
52	Adenosine Receptor 2A Blockade Increases the Efficacy of Antiâ€"PD-1 through Enhanced Antitumor T-cell Responses. Cancer Immunology Research, 2015, 3, 506-517.	3.4	262
53	CD3^{bright} signals on Î³Î´ T cells identify ILâ€17Aâ€producing Vî³6Vî´1⁺ T cells. Immunology and Cell Biology, 2015, 93, 198-212.	2.3	68
54	Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. Immunotherapy, 2015, 7, 499-512.	2.0	18

#	Article	IF	Citations
55	Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Medicine, 2015, 13, 202.	5.5	177
56	CD73: A potential biomarker for anti-PD-1 therapy. OncoImmunology, 2015, 4, e1046675.	4.6	33
57	Cross-talk between tumors can affect responses to therapy. OncoImmunology, 2015, 4, e975572.	4.6	7
58	CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11091-11096.	7.1	406
59	A_{2A}blockade enhances anti-metastatic immune responses. OncoImmunology, 2013, 2, e26705.	4.6	17
60	Blockade of A _{2A} receptors potently suppresses the metastasis of CD73 ⁺ tumors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14711-14716.	7.1	306
61	Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells. Clinical Cancer Research, 2013, 19, 5636-5646.	7.0	598
62	CD73-Deficient Mice Are Resistant to Carcinogenesis. Cancer Research, 2012, 72, 2190-2196.	0.9	178
63	CD73: a potent suppressor of antitumor immune responses. Trends in Immunology, 2012, 33, 231-237.	6.8	310
64	Activation of p38 mitogen-activated protein kinase is critical step for acquisition of effector function in cytokine-activated T cells, but acts as a negative regulator in T cells activated through the T-cell receptor. Immunology, 2011, 132, 104-110.	4.4	24
65	Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16717-16722.	7.1	48